Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.

Objectives: To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action.

Method: The articles selected for the review were identified through searches in English, Portuguese, and Spanish in the electronic databases ISI Web of Knowledge, SciELO, PubMed, and PsycINFO, combining the search terms "cannabidiol and anxiolytic", "cannabidiol and anxiolytic-like", and "cannabidiol and anxiety". The reference lists of the publications included, review articles, and book chapters were handsearched for additional references.

[Translation and cross-cultural adaptation of the Recent-Onset Arthritis Disability (ROAD) index into Brazilian Portuguese].

Introduction: The increasing search for the psychological treatment of patients with chronic diseases and with clinical indications for the control of physical and psychological capacities has revealed a need for instruments aimed at assessing these patients. Rheumatoid arthritis is a condition that has been widely studied with a focus on the development of new drugs and treatment approaches. However, psychometric instruments developed for this specific population are still rare.